Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

SER-287

Microbiome therapy · developed by Seres Therapeutics

Phase 2 Most advanced trial (none active)

MCRB Developer

1 Registered trials

What is SER-287?

SER-287 is a purified suspension of encapsulated eubacterial spores studied in ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Microbiome therapy
Therapy area: Gastroenterology
Developer: Seres Therapeutics, Inc. (MCRB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: 6GU6LU5E7R

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03759041	Phase 2	Ulcerative Colitis	Terminated	MCRB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

More from Seres Therapeutics

SER-155 Phase 1 SER-262 Phase 1

Sources

ClinicalTrials.gov NCT03759041

Updated Oct 3, 2026. Something wrong or missing? Report it on the MCRB page.

Follow MCRB, the company behind SER-287

See MCRB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MCRB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z